Editorial-Orientierung von MedAPI — kein Bestandteil der Kodieranweisung.
C13 covers primary malignant neoplasms arising in the hypopharynx, including the postcricoid region, hypopharyngeal aspect of the aryepiglottic fold, posterior hypopharyngeal wall, overlapping sites, and unspecified hypopharyngeal sites. Malignancy of the pyriform sinus is classified separately under C12.
Common Histologies
- Squamous cell carcinoma, by far the most common histology
- Less commonly, salivary-type carcinomas, neuroendocrine carcinomas, sarcomas, or other rare tumors
Major risk factors include tobacco use and heavy alcohol consumption. Nutritional deficiency and Plummer–Vinson syndrome are associated particularly with postcricoid carcinoma. Human papillomavirus has a less established role than in oropharyngeal cancer.
Common Symptoms
Hypopharyngeal cancers may remain clinically occult until locally advanced. Presentations can include:
- Progressive dysphagia or odynophagia (R13.10)
- Persistent sore throat or globus sensation (R09.A2) (R09.A2)
- Referred otalgia (H92.09)
- Hoarseness or voice change (R49.0)
- Neck mass from regional nodal disease (R22.1)
- Coughing or aspiration during swallowing (R13.12)
- Hemoptysis (R04.2), weight loss (R63.4), or airway symptoms (R06.89)
Diagnosis
Evaluation generally includes complete head and neck examination, flexible nasopharyngolaryngoscopy, and biopsy for histopathologic confirmation. Contrast-enhanced CT or MRI assesses local extent and cervical lymph nodes. PET/CT may be used for advanced disease, occult nodal involvement, distant metastases, or synchronous primary tumors. Direct laryngoscopy and esophagoscopy may help define tumor boundaries and evaluate adjacent mucosa.
Staging
AJCC TNM staging is based on primary tumor extent, regional cervical lymph-node involvement, and distant metastasis. Important local features include invasion of the larynx, esophagus, thyroid or cricoid cartilage, deep neck soft tissues, prevertebral fascia, or major vascular structures. Regional nodal disease is common at presentation and may be bilateral because of hypopharyngeal lymphatic drainage.
Molecular Markers
Routine biomarker selection depends on disease setting and planned therapy. Unlike oropharyngeal squamous cell carcinoma, p16 or HPV positivity does not define a separate hypopharyngeal staging system. PD-L1 testing may inform systemic treatment selection in recurrent or metastatic squamous cell carcinoma. Broader molecular testing may be considered in advanced disease or uncommon histologies.
Common Treatments
Treatment is individualized by site, stage, resectability, swallowing and laryngeal function, comorbidity, and patient preference. Options may include:
- Definitive radiation therapy with concurrent systemic therapy
- Surgical resection, potentially including partial or total pharyngolaryngectomy, with appropriate neck management
- Postoperative radiation or chemoradiation for adverse pathologic features
- Induction systemic therapy in selected organ-preservation strategies
- Immunotherapy, cytotoxic chemotherapy, or targeted therapy for recurrent or metastatic disease
- Nutritional, speech, swallowing, dental, airway, and tobacco/alcohol cessation support
Scope Note
C13 identifies the primary anatomic site as the hypopharynx and allows further specification of certain subsites, overlapping lesions, or an unspecified hypopharyngeal site. It does not encode histologic type, grade, TNM stage, HPV or other biomarker status, treatment, or recurrence. It should not be used for a metastasis to the hypopharynx or for distant metastatic disease from a hypopharyngeal primary; secondary malignancies are classified separately. Primary malignant neoplasm of the pyriform sinus is excluded from C13 and classified under C12. Tobacco use, dependence, history, or smoke exposure may be captured separately when documented.